Lopos 50 mg (Tablet)
Unit Price: ৳ 6.00 (10 x 10: ৳ 600.00)
Strip Price: ৳ 60.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Losartan potassium |
| Company | Zenith pharmaceuticals ltd |
Indications
- Treatment of hypertension
- Renal protection in type-2 diabetic patients with proteinuria
Pharmacology
- Non-peptide orally active angiotensin II receptor blocker
- Binds to AT1 receptor in various tissues
- Reduces vasoconstriction and aldosterone release
Dosage & Administration
- Usual starting and maintenance dose of 50 mg once daily
- 25 mg twice daily if initial dose inadequate
- 25 mg once daily for patients with intravascular volume-depletion
- Total daily dose ranges from 25 mg to 100 mg
- Lower starting dose of 25 mg once daily for patients over 75 years
Interaction
- Reduced levels of active metabolite with rifampicin and fluconazole
- Potentiation of antihypertensive effects with concomitant use of hydrochlorothiazide
- Increased serum potassium with concomitant use of potassium-sparing diuretics or supplements
- Attenuated antihypertensive effect with non-steroidal anti-inflammatory drug indomethacin
Contraindications
- Contraindicated in pregnant women
- Hypersensitivity to any component of the product
- Should not be administered with Aliskiren in patients with diabetes
Side Effects
- Mild and transient side effects
- Common side effects include dizziness, diarrhea, nasal congestion, cough, and upper respiratory infection
- Other side effects include fatigue, edema, abdominal pain, chest pain, nausea, headache, and pharyngitis
Pregnancy & Lactation
- Pregnancy Category D
- Risk to fetus increases if administered during second or third trimester
- Excretion in human milk unknown, potential for adverse effects on nursing infant
Precautions & Warnings
- Reduces fetal renal function and increases fetal and neonatal morbidity and death if used during second and third trimesters of pregnancy
- Symptomatic hypotension may occur in intravascularly depleted patients
- Significantly increased plasma concentration in cirrhotic patients
- Changes in renal function including renal failure reported in renal impaired patients
Use in Special Populations
- No initial dosage adjustment necessary in patients with mild renal impairment
- Lower starting dose recommended for moderate to severe renal impairment or patients on dialysis
- Special considerations for patients with intravascular volume depletion
- Consider lower dose for patients with history of hepatic impairment
Therapeutic Class
- Angiotensin II receptor blocker
Storage Conditions
- Keep in a dry place away from light and heat
- Keep out of the reach of children